Medicine
Juluca 50 mg/25 mg tablet
Juluca 50 mg/25 mg tablet is a prescription medicine containing Dolutegravir and Rilpivirine for oral use, marketed by ViiV Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Dolutegravir and Rilpivirine
- Brand
- Juluca
- Strength
- 50 mg/25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- ViiV Healthcare
- Manufacturer
- ViiV Healthcare
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR21 Dolutegravir and Rilpivirine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 November 2017
- Identifiers
- RxCUI 1989500, 1989506DailyMed set ID 806653d1-bf35-4924-b999-ad5d21821cc1NDC 49702-242Application NDA210192
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 49702-242-13 | ViiV Healthcare | 21 November 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Dolutegravir and Rilpivirine is a fixed-dose combination of a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor and a human immunodeficiency virus integrase strand transfer inhibitor. It is available as tablets for oral use. MedsAcross supplies Dolutegravir and Rilpivirine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Dolutegravir and RilpivirineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Juluca prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
- Juluca: European public assessment report (EPAR) · European Medicines Agency
Need Juluca 50 mg/25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.